Pharma News

Researchers have identified a potential new strategy to limit the spread of breast cancer to the lungs by targeting the metabolic processes that help cancer cells survive and grow. The study, published in Cancer Biology & Medicine in March 2026, suggests that mitochondrial uncouplers could suppress a key metabolic pathway used by cancer cells and significantly reduce lung metastasis in mouse models.

U.S. Food and Drug Administration (FDA) has granted accelerated approval to Jemperli (dostarlimab-gxly) as a standalone treatment for certain adults with previously untreated stage II or stage III locally advanced rectal cancer, potentially allowing them to avoid surgery, radiation and chemotherapy.

The Central Drugs Standard Control Organization (CDSCO) has issued a clarification stating that pharmaceutical companies may not need a separate Export No Objection Certificate (NOC) for certain already approved recombinant DNA (r-DNA) drug products intended for export.

Eli Lilly and Company has announced new analyses of clinical trial data showing that its drug Omvoh (mirikizumab-mrkz) helped some patients with moderately to severely active ulcerative colitis and Crohn’s disease achieve multiple treatment goals simultaneously at one year.

To strengthen India’s clinical research capabilities and expand the country’s participation in global clinical trials, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, and AstraZeneca India have partnered to extend clinical trial capabilities beyond the metros, building a trained workforce and inspection-ready sites in 25 emerging research geographies across India.

Biocon Limited has entered into a global patent settlement and licence agreement with Genentech, a member of the Roche Group, resolving pending disputes over Pebrilzo® (bPertuzumab), its biosimilar version of Perjeta® (pertuzumab), a biologic medicine used in the treatment of HER2-positive breast cancer.

A common asthma medication improves motor skills and muscle strength in children with congenital myopathies, a group of incurable muscle diseases. In a study, children receiving the drug were able to both walk and stand up more quickly.